Diabetes-Induced Reactive Oxygen Species: Mechanism of Their Generation and Role in Renal Injury
Diabetes induces the onset and progression of renal injury through causing hemodynamic dysregulation along with abnormal morphological and functional nephron changes. The most important event that precedes renal injury is an increase in permeability of plasma proteins such as albumin through a damaged glomerular filtration barrier resulting in excessive urinary albumin excretion (UAE). Moreover, once enhanced UAE begins, it may advance renal injury from progression of abnormal renal hemodynamics, increased glomerular basement membrane (GBM) thickness, mesangial expansion, extracellular matrix accumulation, and glomerulosclerosis to eventual end-stage renal damage. Interestingly, all these pathological changes are predominantly driven by diabetes-induced reactive oxygen species (ROS) and abnormal downstream signaling molecules. In diabetic kidney, NADPH oxidase (enzymatic) and mitochondrial electron transport chain (nonenzymatic) are the prominent sources of ROS, which are believed to cause the onset of albuminuria followed by progression to renal damage through podocyte depletion. Chronic hyperglycemia and consequent ROS production can trigger abnormal signaling pathways involving diverse signaling mediators such as transcription factors, inflammatory cytokines, chemokines, and vasoactive substances. Persistently, increased expression and activation of these signaling molecules contribute to the irreversible functional and structural changes in the kidney resulting in critically decreased glomerular filtration rate leading to eventual renal failure.
Top-30
Journals
1
2
3
4
5
6
7
|
|
International Journal of Molecular Sciences
7 publications, 3.59%
|
|
Antioxidants
4 publications, 2.05%
|
|
Biomedicine and Pharmacotherapy
4 publications, 2.05%
|
|
Journal of Food Biochemistry
4 publications, 2.05%
|
|
Experimental and Therapeutic Medicine
3 publications, 1.54%
|
|
Food and Chemical Toxicology
3 publications, 1.54%
|
|
Journal of Cellular Physiology
3 publications, 1.54%
|
|
Evidence-based Complementary and Alternative Medicine
3 publications, 1.54%
|
|
BioMed Research International
3 publications, 1.54%
|
|
Current Medicinal Chemistry
2 publications, 1.03%
|
|
Nutrients
2 publications, 1.03%
|
|
Frontiers in Pharmacology
2 publications, 1.03%
|
|
International Journal of Diabetes in Developing Countries
2 publications, 1.03%
|
|
BMC Nephrology
2 publications, 1.03%
|
|
Scientific Reports
2 publications, 1.03%
|
|
BMC Complementary and Alternative Medicine
2 publications, 1.03%
|
|
Journal of Diabetes and its Complications
2 publications, 1.03%
|
|
PLoS ONE
2 publications, 1.03%
|
|
Life Sciences
2 publications, 1.03%
|
|
Free Radical Biology and Medicine
2 publications, 1.03%
|
|
International Journal of Biological Macromolecules
2 publications, 1.03%
|
|
Periodontology 2000
2 publications, 1.03%
|
|
FASEB Journal
2 publications, 1.03%
|
|
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
2 publications, 1.03%
|
|
Chemical Engineering Journal
2 publications, 1.03%
|
|
Pharmacognosy Magazine
2 publications, 1.03%
|
|
Endocrine, Metabolic and Immune Disorders - Drug Targets
1 publication, 0.51%
|
|
Current Enzyme Inhibition
1 publication, 0.51%
|
|
Current Bioactive Compounds
1 publication, 0.51%
|
|
1
2
3
4
5
6
7
|
Publishers
5
10
15
20
25
30
35
40
45
50
|
|
Elsevier
46 publications, 23.59%
|
|
Springer Nature
26 publications, 13.33%
|
|
MDPI
25 publications, 12.82%
|
|
Wiley
20 publications, 10.26%
|
|
Taylor & Francis
12 publications, 6.15%
|
|
Bentham Science Publishers Ltd.
10 publications, 5.13%
|
|
Hindawi Limited
10 publications, 5.13%
|
|
Frontiers Media S.A.
7 publications, 3.59%
|
|
Spandidos Publications
4 publications, 2.05%
|
|
American Chemical Society (ACS)
3 publications, 1.54%
|
|
Ovid Technologies (Wolters Kluwer Health)
3 publications, 1.54%
|
|
SAGE
3 publications, 1.54%
|
|
Mary Ann Liebert
2 publications, 1.03%
|
|
Maad Rayan Publishing Company
2 publications, 1.03%
|
|
Public Library of Science (PLoS)
2 publications, 1.03%
|
|
Federation of American Societies for Experimental Biology (FASEB)
2 publications, 1.03%
|
|
Walter de Gruyter
2 publications, 1.03%
|
|
Cold Spring Harbor Laboratory
2 publications, 1.03%
|
|
IntechOpen
2 publications, 1.03%
|
|
F1000 Research
1 publication, 0.51%
|
|
Impact Journals
1 publication, 0.51%
|
|
Portland Press
1 publication, 0.51%
|
|
Pharmaceutical Society of Korea
1 publication, 0.51%
|
|
Baishideng Publishing Group
1 publication, 0.51%
|
|
Royal Society of Chemistry (RSC)
1 publication, 0.51%
|
|
King Saud University
1 publication, 0.51%
|
|
AIP Publishing
1 publication, 0.51%
|
|
Universitas Gadjah Mada
1 publication, 0.51%
|
|
Korean Society of Applied Pharmacology
1 publication, 0.51%
|
|
5
10
15
20
25
30
35
40
45
50
|
- We do not take into account publications without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.